12:00 AM
 | 
Nov 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Dolutegravir: Phase III data

The open-label, international Phase III VIKING-3 trial in 183 HIV-1 infected, antiretroviral therapy (ART)-experienced patients with current or historical failure on an integrase inhibitor-containing regimen showed that the addition of twice-daily 50 mg dolutegravir to the current failing regimen significantly reduced mean HIV-1 RNA levels from baseline to day 8, a co-primary endpoint, by 1.4 log10 copies/mL (p<0.001). Additionally, 63% of patients achieved HIV-1 RNA levels <50...

Read the full 311 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >